MTOR ACTIVATION TRIGGERS IL-4 PRODUCTION AND NECROTIC DEATH OF DOUBLE-NEGATIVE T CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYHTHEMATOSUS

Por Lai, Zhi-Wei, Borsuk, Rebecca, Shadakshari, Ashwini, Yu, Jianghong, Dawood, Maha, Garcia, Ricardo, Francis, Lisa, Tily, Hajra, Bartos, Adam, Faraone, Stephen V., Phillips, Paul, Perl, Andras
Publicado em 2013

mTOR activation triggers proinflammatory expansion of IL-4-producing and necrosis-prone double-negative T cells, precedes flares, and serves as target for treatment in patients wit...

Por Lai, Zhi-Wei, Borsuk, Rebecca, Shadakshari, Ashwini, Yu, Jianghong, Dawood, Maha, Garcia, Ricardo, Francis, Lisa, Tily, Hajra, Bartos, Adam, Faraone, Stephen V, Phillips, Paul, Perl, Andras
Publicado em 2014

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial

Por Lai, Zhi-Wei, Kelly, Ryan, Winans, Thomas, Marchena, Ivan, Shadakshari, Ashwini, Yu, Julie, Dawood, Maha, Garcia, Ricardo, Tily, Hajra, Francis, Lisa, Faraone, Stephen V, Phillips, Paul E, Perl, Andras
Publicado no Lancet (2018)